Report a data issue, formatting problem, or request follow-up. Our team responds within one business day.
Be the first to review this report.
Celecoxib capsules (patent brand name: CELEBREX), is a new generation of non-steroidal anti-inflammatory and analgesic drugs, mainly through the selective inhibition of coX-2 (COX-2) to inhibit the production of prostaglandins, achieve anti-inflammatory and analgesic effects. The drug is used to relieve symptoms and signs of osteoarthritis and rheumatoid arthritis in adults and has fewer gastrointestinal side effects than traditional non-steroidal anti-inflammatory drugs.
Data show that more than 400 million people worldwide are currently affected by joint diseases.
The prevalence of osteoarthritis is 17 percent among people aged 40, 62 percent among people over 60 and 80 percent among people over 75.
The number of patients with arthritis in mainland China is more than 10% of the total population, well over 100 million, and the incidence of arthritis increases with age, and the number of patients is still increasing.
At present, the burden of chronic diseases will increase by 40% due to the aging of the population.
As the population ages, anti-inflammatory and anti-rheumatic drugs will enter a phase of rapid growth.
Globally, whether prescription drugs or non-prescription drugs, Xibu is widely used in clinical practice.
At present, the best seller in the international market is Celixib. Celixib market will continue to grow steadily in the next few years.
At present, the global Celecoxib market is basically occupied by Pfizer, which has formed an oligopoly.
It accounted for 63.39% of the global market in 2019.
As of 2019, China relies entirely on Pfizer for celecoxib imports.
Since 2020, some domestic drug companies have been gradually approved by FDA and CFDA. The introduction of celecoxib generic drugs by local companies will break the monopoly of import.
This report presents an overview of global market for Celecoxib, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Celecoxib, also provides the sales of main regions and countries. Of the upcoming market potential for Celecoxib, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Celecoxib sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Celecoxib market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Celecoxib sales, projected growth trends, production technology, application and end-user industry.
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Celecoxib in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Celecoxib manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Celecoxib sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
You may also be interested in
